Growth Metrics

Emergent BioSolutions (EBS) Total Current Liabilities (2016 - 2025)

Emergent BioSolutions' Total Current Liabilities history spans 16 years, with the latest figure at $132.2 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 18.6% year-over-year to $132.2 million; the TTM value through Dec 2025 reached $132.2 million, down 18.6%, while the annual FY2025 figure was $132.2 million, 18.6% down from the prior year.
  • Total Current Liabilities reached $132.2 million in Q4 2025 per EBS's latest filing, down from $136.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $1.2 billion in Q4 2022 to a low of $111.9 million in Q1 2025.
  • Average Total Current Liabilities over 5 years is $444.0 million, with a median of $367.8 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 387.84% in 2023, then plummeted 82.24% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $374.0 million in 2021, then surged by 228.58% to $1.2 billion in 2022, then plummeted by 47.0% to $651.3 million in 2023, then tumbled by 75.07% to $162.4 million in 2024, then dropped by 18.6% to $132.2 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Total Current Liabilities are $132.2 million (Q4 2025), $136.5 million (Q3 2025), and $127.1 million (Q2 2025).